Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027

NEW YORK, Sept. 20, 2018 /PRNewswire/ --

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027

Summary

Read the full report: https://www.reportlinker.com/p05568479

For nearly two decades, the Cytomegalovirus (CMV) therapeutics landscape has been dominated by ganciclovir and valganciclovir, with modest growth in the form of additional antivirals targeting DNA replication. The 2017 approval of Prevymis in the US marked the first major shift in therapeutic strategy to come to theCytomegalovirus (CMV) market in several years, potentially setting the stage for other experimental therapies for Cytomegalovirus (CMV) currently in clinical development.

Cytomegalovirus (CMV) is a ? human herpesvirus (HHV-5) of the herpesviridae family.Exposure to the virus can result in lytic infection, producing symptoms that range from those of a common cold to more serious morbidities, including hepatitis and pneumonitis.

Cytomegalovirus (CMV) also has the capacity to establish life-long latent infections, incorporating genomic DNA into host cells without detectable viral gene expression.Although largely asymptomatic in immunocompetent adults, Cytomegalovirus (CMV) infection is a clinically significant disease in patients with compromised immune systems or those receiving immunosuppressive therapy.

Particularly vulnerable patients include solid organ transplant (SOT), bone marrow transplant (BMT), hematopoietic stem cell transplant (HSCT), and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) patients, as well as newborns that acquire the infection by transmission from the mother through the placenta.

The Cytomegalovirus (CMV) market is expected to experience moderate growth over the forecast period (2017-2027).The market features several antivirals that are used for both treatment of clinically significant Cytomegalovirus (CMV) infections and prophylaxis in patients considered at high risk for Cytomegalovirus (CMV) infection.

The global Cytomegalovirus (CMV) market across the 7MM (US, France, Germany, Italy, Spain, the UK and Japan) was valued over $240M in 2017. Over the 10-year forecast period, the Cytomegalovirus (CMV) market is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.5%.

The report "Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027", helps in analyzing the cytomegalovirus (CMV) market and treatment landscape, providing an overview and forecast of the market dynamics from 2017 to 2027.

Key Questions Answered
- How will the Cytomegalovirus (CMV) therapeutic market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2017-2027?
- What are the most promising late-stage pipeline drugs for CMV?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another and against existing treatment options?
- What are the remaining unmet needs in Cytomegalovirus (CMV) treatment management?
- What drivers and barriers will affect Cytomegalovirus (CMV) therapeutics sales in the 7MM over the forecast period?

Scope
- Overview of CMV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline CMV market revenue from 2017-2027. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment and prophylactic options, unmet needs and opportunities, and the drivers and barriers affecting CMV therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global CMV therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global CMV therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CMV therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Read the full report: https://www.reportlinker.com/p05568479

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker